Patents Assigned to Modulation Therapeutics, Inc.
  • Radiotherapeutic and companion imaging agents to target MC1R
    Patent number: 12508329
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: December 30, 2025
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., MODULATION THERAPEUTICS, INC., WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
  • TARGETING ERO1 ALPHA WITH AURONE DERIVATIVES
    Publication number: 20250064773
    Abstract: Compounds and pharmaceutical compositions comprising a derivative of sulfuretin are provided that are inhibitors of the endoplasmic reticulum oxidoreductin-1 alpha. A method of treating a patient having cancer comprising administering to the patient a therapeutically effective amount of a compound that is a derivative of sulfuretin that are inhibitors of the endoplasmic reticulum oxidoreductin-1 alpha to a patient is disclosed.
    Type: Application
    Filed: December 13, 2022
    Publication date: February 27, 2025
    Applicants: West Virginia University Board of Governors on behalf of West Virginia University, Modulation Therapeutics, Inc.
    Inventors: Lori Hazelhurst, Werner Geldenhuys, Sridhar Reddy Kaulagari
  • Cyclic peptide compounds and methods of use thereof
    Patent number: 12060438
    Abstract: Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 13, 2024
    Assignee: Modulation Therapeutics, Inc.
    Inventors: Mark McLaughlin, Lori Hazlehurst